{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:33:35Z","timestamp":1761964415651},"reference-count":8,"publisher":"American Society of Consultant Pharmacists","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2012,7,1]]},"DOI":"10.4140\/tcp.n.2012.482","type":"journal-article","created":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T01:49:18Z","timestamp":1345600158000},"page":"482-492","source":"Crossref","is-referenced-by-count":5,"title":["Black Box Warnings: What Do They Mean to Pharmacists and Patients"],"prefix":"10.4140","volume":"27","author":[{"given":"Caren McHenry","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Borgelt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2012,7,11]]},"reference":[{"key":"1","unstructured":"Food and Drug Administration. Guidance for industry. Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products\u2014content and format. Available at http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm075096.pdf. Accessed February 20, 2012. <a target=\"_blank\" href='http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm075096.pdf'>http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm075096.pdf<\/a>"},{"key":"2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","article-title":"Timing of new black box warnings and withdrawals for prescription medications","volume":"287","author":"KE Lasser","year":"2002","journal-title":"JAMA"},{"key":"3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaci.2005.10.031","article-title":"Black box 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit\/risk","volume":"117","author":"S Murphy","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"4","unstructured":"Dusetzina SB, Higashi AS, Dorsey ER et al. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Available at http:\/\/journals.lww.com\/lww-medicalcare\/Abstract\/publishahead\/Impact_of_FDA_Drug_Risk_Communications_on_Health.99485.aspx. Accessed February 20, 2012. <a target=\"_blank\" href='http:\/\/www.journals.lww.com\/lww-medicalcare\/Abstract\/publishahead\/Impact_of_FDA_Drug_Risk_Communications_on_Health.99485.aspx'>http:\/\/journals.lww.com\/lww-medicalcare\/Abstract\/publishahead\/Impact_of_FDA_Drug_Risk_Communications_on_Health.99485.aspx<\/a>"},{"key":"5","doi-asserted-by":"crossref","unstructured":"McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; September 8: e1001098. doi:10.1371\/journal.pmed.1001098 Accessed February 20, 2012.","DOI":"10.1371\/journal.pmed.1001098"},{"key":"6","doi-asserted-by":"crossref","unstructured":"The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.","DOI":"10.1056\/NEJMoa1001282"},{"key":"7","unstructured":"Products with \u201cblack box\u201d warnings. Pharmacist's Letter\/ Prescriber's Letter 2006;22:220-332."},{"key":"8","unstructured":"Federal Register March 27, 2008;73. Available at http:\/\/www.gpo.gov\/fdsys\/pkg\/FR-2008-03-27\/pdf\/E8-6201.pdf. Accessed December 20, 2011. <a target=\"_blank\" href='http:\/\/www.gpo.gov\/fdsys\/pkg\/FR-2008-03-27\/pdf\/E8-6201.pdf'>http:\/\/www.gpo.gov\/fdsys\/pkg\/FR-2008-03-27\/pdf\/E8-6201.pdf<\/a>"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T05:51:13Z","timestamp":1551937873000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2012\/00000027\/00000007\/art00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,1]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7,1]]}},"alternative-id":["P74R0R7483220896"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2012.482","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7,1]]}}}